✦ LIBER ✦

Low weight predicts neutropenia and peginterferon alfa-2a dose reductions during treatment for chronic hepatitis C

✍ Scribed by Y. Rotman; L. Katz; M. Cohen; O. Cohen-Ezra; V. Manhaim; M. Braun; Z. Ben-Ari; R. Tur-Kaspa

Book ID: 108886234
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 129 KB
Volume: 16
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2009.01079.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk factors for infection during treatm

Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C

✍ Robert Roomer; Bettina E. Hansen; Harry L. A. Janssen; Robert J. de Knegt 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB 👁 2 views

Neutropenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C virus (HCV) infection is a common cause of dose reductions of peginterferon alfa. These reductions are performed to prevent bacterial and fungal infections, which are common during HCV treatment and can be att

Peginterferon alfa-2b and weight-based o

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

✍ Ira M. Jacobson; Robert S. Brown Jr; Bradley Freilich; Nezam Afdhal; Paul Y. Kwo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Clifford A. Brass, 15 and the WIN-R Study Group This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with

Low- and standard-dose peginterferon alf

Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response

✍ Y. ROTMAN; B. B. BORG; A. SOZA; J. J. FELD; A. A. MODI; R. LOOMBA; G. LUTCHMAN; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB

Incidence of Neutropenia and Infections

Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon Alfa-2a or Alfa-2b Plus Ribavirin

✍ M. G. Antonini; S. Babudieri; I. Maida; C. Baiguera; B. Zanini; L. Fenu; G. Dett 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 271 KB

Randomised clinical trial: escitalopram

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C

✍ R. J. de Knegt; G. Bezemer; A. R. Van Gool; J. P. H. Drenth; B. E. Hansen; H. A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.